| Type | Title | Date Released | |
|---|---|---|---|
FWP | Form FWP New | ||
424B5 | Form 424B5 New | ||
144 | Form 144 | ||
SCHEDULE 13G/A | BlackRock, Inc. (Filed by) | ||
6-K | Novartis AG Files Form 6-K Including Q3 2026 Financial Report | ||
6-K | Novartis provides update on delpacibart etedesiran (del-desiran) Phase III HARBOR study for DM1 | ||
6-K | Novartis Announces Topline Results for Phase III Lp(a)HORIZON Trial of Pelacarsen | ||
6-K | Novartis Announces Positive Phase III Results for Remibrutinib in Relapsing Multiple Sclerosis | ||
6-K | Form 6-K | ||
6-K | Novartis Phase I/II Study of Delpacibart Braxlosiran (Del-brax) for FSHD Meets Primary Biomarker Endpoint | ||
144 | Form 144 | ||
6-K | Form 6-K |